Cargando…
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
Hutchinson–Gilford progeria syndrome (HGPS) is an ultra-rare multisystem premature aging disorder that leads to early death (mean age of 14.7 years) due to myocardial infarction or stroke. Most cases have a de novo point mutation at position G608G within exon 11 of the LMNA gene. This mutation leads...
Autores principales: | Arnold, Rouven, Vehns, Elena, Randl, Hannah, Djabali, Karima |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307450/ https://www.ncbi.nlm.nih.gov/pubmed/34299092 http://dx.doi.org/10.3390/ijms22147474 |
Ejemplares similares
-
Impact of MnTBAP and Baricitinib Treatment on Hutchinson–Gilford Progeria Fibroblasts
por: Vehns, Elena, et al.
Publicado: (2022) -
Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
por: Liu, Chang, et al.
Publicado: (2019) -
Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts
por: Gabriel, Diana, et al.
Publicado: (2017) -
Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria
por: Yang, Shao H., et al.
Publicado: (2010) -
Defective Lamin A-Rb Signaling in Hutchinson-Gilford Progeria Syndrome and Reversal by Farnesyltransferase Inhibition
por: Marji, Jackleen, et al.
Publicado: (2010)